Does the cost-effectiveness analysis report results separately for patients who have different baseline risks?
The cost-effectiveness of any orthopaedic strategy will vary depending on the individual patients baseline risks. In other words, the costs and outcomes of a surgical intervention are related to the baseline risk of the condition under scrutiny. Patients who are at high risk will generally benefit more from a procedure than those at low risk. [10] Examples of baseline risk include age, sex, stage of disease, co-morbidities, work status and activity level. Certain subgroups of patients may have a higher risk of a condition and are more likely to benefit from the new surgical intervention. Therefore, the ICERs may be dependent on the patient’s ability to benefit from the surgical intervention. It is generally recommended that cost-effectiveness analyses report results separately for patients who have different baseline risks. For example, an economic analysis may present the ICER for males and then a separate ICER for females. In the economic analysis conducted by Bozic et al. , the only
Related Questions
- Why do substances analyzed in both the analysis charts and the Specify Criteria tool often produce different results?
- Does the cost-effectiveness analysis report results separately for patients who have different baseline risks?
- Why does the report containing my results indicate Form F-SR was used when a different form was used?
